WallStSmart

CeriBell, Inc (CBLL)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 25239% more annual revenue ($25.84B vs $101.96M). SYK leads profitability with a 14.4% profit margin vs -64.7%. SYK earns a higher WallStSmart Score of 67/100 (B-).

CBLL

Avoid

28

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 3/9Altman Z: 1.34

SYK

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CBLL.

SYKSignificantly Overvalued (-19.9%)

Margin of Safety

-19.9%

Fair Value

$229.73

Current Price

$275.56

$45.83 premium

UndervaluedFair: $229.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CBLL2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
32.5%10/10

Revenue surging 32.5% year-over-year

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

SYK4 strengths · Avg: 8.3/10
Market CapQuality
$105.70B9/10

Large-cap with strong market position

Operating MarginProfitability
27.0%8/10

Strong operational efficiency at 27.0%

EPS GrowthGrowth
44.1%8/10

Earnings expanding 44.1% YoY

Free Cash FlowQuality
$1.06B8/10

Generating 1.1B in free cash flow

Areas to Watch

CBLL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$906.87M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-51.4%2/10

ROE of -51.4% — below average capital efficiency

SYK2 concerns · Avg: 3.5/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CBLL

The strongest argument for CBLL centers on Revenue Growth, Debt/Equity. Revenue growth of 32.5% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : CBLL

The primary concerns for CBLL are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CBLL profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

CBLL is growing revenue faster at 32.5% — sustainability is the question.

SYK generates stronger free cash flow (1.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (67/100 vs 28/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CeriBell, Inc

HEALTHCARE · MEDICAL DEVICES · USA

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?